[go: up one dir, main page]

BRPI0607093A2 - polimorfo cristalino de monoidrato de sal monossódico de ácido 3-(n-metil-n-pentil)amino-1-hidroxipropano-1, 1-difosfÈnico, ibandronato, processo para a preparação de um polimorfo de ibandronato cristalino, e composição farmacêutica que o compreende - Google Patents

polimorfo cristalino de monoidrato de sal monossódico de ácido 3-(n-metil-n-pentil)amino-1-hidroxipropano-1, 1-difosfÈnico, ibandronato, processo para a preparação de um polimorfo de ibandronato cristalino, e composição farmacêutica que o compreende

Info

Publication number
BRPI0607093A2
BRPI0607093A2 BRPI0607093-0A BRPI0607093A BRPI0607093A2 BR PI0607093 A2 BRPI0607093 A2 BR PI0607093A2 BR PI0607093 A BRPI0607093 A BR PI0607093A BR PI0607093 A2 BRPI0607093 A2 BR PI0607093A2
Authority
BR
Brazil
Prior art keywords
polymorph
crystalline
amino
methyl
hydroxypropane
Prior art date
Application number
BRPI0607093-0A
Other languages
English (en)
Inventor
Uwe Eiermann
Bernd Junghans
Bernhard Knipp
Tim Sattelkau
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36088250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0607093(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0607093A2 publication Critical patent/BRPI0607093A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)

Abstract

POLIMORFO CRISTALINO DE MONOIDRATO DE SAL MONOSSóDICO DE áCIDO 3- (N-METIL-N-PENTIL) AMINO-1-HIDROXIPROPANO-1, 1-DIFOSFÈNICO, IBANDRONATO, PROCESSO PARA A PREPARAçãO DE UM POLIMORFO DE IBANDRONATO CRISTALINO, E COMPOSIçãO FARMACêUTICA QUE O COMPREENDE. Refere-se a presente invenção a um novo polimorfo cristalino de monoidrato de sal monossódico de ácido 3- (N-metil-N-pentil) amino-1-hidroxipropano-1,1-difosfânico (Ibandronato) com a fórmula (1)
BRPI0607093-0A 2005-02-01 2006-01-24 polimorfo cristalino de monoidrato de sal monossódico de ácido 3-(n-metil-n-pentil)amino-1-hidroxipropano-1, 1-difosfÈnico, ibandronato, processo para a preparação de um polimorfo de ibandronato cristalino, e composição farmacêutica que o compreende BRPI0607093A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05100687 2005-02-01
PCT/EP2006/000579 WO2006081962A1 (en) 2005-02-01 2006-01-24 Ibandronate polymorph b

Publications (1)

Publication Number Publication Date
BRPI0607093A2 true BRPI0607093A2 (pt) 2009-08-04

Family

ID=36088250

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607093-0A BRPI0607093A2 (pt) 2005-02-01 2006-01-24 polimorfo cristalino de monoidrato de sal monossódico de ácido 3-(n-metil-n-pentil)amino-1-hidroxipropano-1, 1-difosfÈnico, ibandronato, processo para a preparação de um polimorfo de ibandronato cristalino, e composição farmacêutica que o compreende

Country Status (20)

Country Link
US (2) US7582789B2 (pt)
EP (3) EP2363401A1 (pt)
JP (2) JP5828607B2 (pt)
KR (1) KR100908530B1 (pt)
CN (1) CN101111505B (pt)
AR (1) AR053119A1 (pt)
AU (1) AU2006210008B2 (pt)
BR (1) BRPI0607093A2 (pt)
CA (1) CA2594717C (pt)
DK (1) DK1848727T3 (pt)
ES (1) ES2543804T3 (pt)
IL (1) IL184720A (pt)
MX (1) MX2007008917A (pt)
NO (1) NO20073755L (pt)
PL (1) PL1848727T3 (pt)
RU (1) RU2387661C2 (pt)
SI (1) SI1848727T1 (pt)
TW (1) TWI374888B (pt)
WO (1) WO2006081962A1 (pt)
ZA (1) ZA200706170B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005025977D1 (de) 2004-08-23 2011-03-03 Teva Pharma Kristalline form des ibandronat-natriums und herstellungsverfahren dafür
EP2363401A1 (en) 2005-02-01 2011-09-07 F. Hoffmann-La Roche AG Ibandronate polymorph B
WO2007074475A2 (en) * 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate
PT103600B (pt) * 2006-11-06 2009-01-30 Hovione Farmaciencia Sa Processo para a preparação de ácidos biosfónicos e seus sais farmaceuticamente aceitáveis
JP2009516004A (ja) * 2006-11-16 2009-04-16 テバ ファーマシューティカル インダストリーズ リミティド イバンドロン酸ナトリウムの結晶形態
SI2144919T1 (sl) * 2007-04-11 2016-02-29 F. Hoffmann-La Roche Ag Večstopenjska sinteza ibandronata
AU2008242788A1 (en) 2007-04-19 2008-10-30 Dr. Reddy's Laboratories Ltd. Ibandronate sodium polymorphs
US20090042839A1 (en) * 2007-08-09 2009-02-12 Sharon Avhar-Maydan Crystalline forms of ibandronate sodium
ES2428699T3 (es) * 2007-10-26 2013-11-08 Chemo Ibérica, S.A. Formas polimórficas de ibandronato de sodio y procedimientos para la preparación del mismo
EP2128166A1 (en) 2008-05-20 2009-12-02 Chemo Ibérica, S.A. Polymorphic forms of Ibandronate sodium and processes for preparation thereof
EP2180003A1 (en) 2008-10-21 2010-04-28 Zentiva, k.s. Preparation of ibandronate trisodium
WO2011016738A1 (en) 2009-08-05 2011-02-10 Zaklady Farmaceutyczne Polpharma Sa A process for the synthesis of 1-hydroxy-3-(n-methylpentylamino) propylidene bisphosphonic acid monosodium salt, monohydrate
EP2609101B1 (en) 2010-07-14 2015-01-28 Pharmathen S.A. Process for the preparation of 3-(n-methyl-n-pentyl)amino-1-hydroxypropane-1,1-diphosphonic acid salt or derivatives thereof
TR201200588A2 (tr) * 2012-01-18 2012-07-23 Koçak Farma İlaç Ve Ki̇mya Sanayi̇ Anoni̇m Şi̇rketi̇ Sodyum ibandronat monohidrat polimorflarini ve polimorflu karışımlarını hazırlamak için prosesler.
KR20200085441A (ko) 2019-01-07 2020-07-15 엠에프씨 주식회사 이반드로네이트의 신규한 결정형 및 이의 제조방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3764604A (en) * 1968-12-17 1973-10-09 Us Army 4-pyridylcarbinolamine anti-malarials
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
TW198039B (pt) * 1988-11-28 1993-01-11 Ciba Geigy Ag
EP0538384A4 (en) * 1990-07-10 1995-04-12 Smithkline Beecham Corp Oxamides
DE19531264A1 (de) * 1995-08-25 1997-02-27 Hoechst Ag Kationische, ungesättigte Saccharide sowie daraus hergestellte Polymerisate und deren Verwendung
IT1303672B1 (it) * 1998-07-28 2001-02-23 Nicox Sa Sali nitrati di farmaci attivi nei disordini ossei
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
RU2220975C2 (ru) 1998-10-16 2004-01-10 Акцо Нобель Н.В. КОМПОЗИЦИЯ С ВЫСОКОЙ СТЕПЕНЬЮ ЧИСТОТЫ, СОДЕРЖАЩАЯ (7α,17α)-17-ГИДРОКСИ-7-МЕТИЛ-19-НОР-17-ПРЕГН-5(10)-ЕН-20-ИН-3-ОН, СПОСОБ ЕЕ ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКИЕ СТАНДАРТНЫЕ ЛЕКАРСТВЕННЫЕ ФОРМЫ
KR100453779B1 (ko) * 1998-12-04 2004-10-20 로쉐 디아그노스틱스 게엠베하 내인공삽입물의 골형성을 개선시키기 위한 이밴드론산염의용도
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
WO2001075080A1 (en) * 2000-03-30 2001-10-11 Research Development Foundation Tyr393 and tyr398 mutants of monoamine oxidase b
CN1404836A (zh) * 2001-09-14 2003-03-26 中生北方生物工程开发研究所 埃本膦酸钠作为预防和治疗骨质疏松症的药物的有效成分的应用
KR20120065435A (ko) * 2002-05-10 2012-06-20 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
MX2007000087A (es) * 2004-06-23 2007-11-06 Teva Pharma Acido ibandronico solido y cristalino.
DE602005025977D1 (de) 2004-08-23 2011-03-03 Teva Pharma Kristalline form des ibandronat-natriums und herstellungsverfahren dafür
DK2662380T3 (en) 2005-02-01 2019-03-18 Atnahs Pharma Uk Ltd Medical use of Ibandronate polymorph A
EP2363401A1 (en) * 2005-02-01 2011-09-07 F. Hoffmann-La Roche AG Ibandronate polymorph B

Also Published As

Publication number Publication date
JP6039755B2 (ja) 2016-12-07
WO2006081962A1 (en) 2006-08-10
AU2006210008B2 (en) 2009-10-08
AR053119A1 (es) 2007-04-25
TWI374888B (en) 2012-10-21
CA2594717C (en) 2015-01-20
PL1848727T3 (pl) 2015-11-30
MX2007008917A (es) 2007-08-21
US20060172976A1 (en) 2006-08-03
ES2543804T3 (es) 2015-08-24
US20090312289A1 (en) 2009-12-17
ZA200706170B (en) 2008-09-25
DK1848727T3 (da) 2015-07-20
EP2610261A1 (en) 2013-07-03
CN101111505A (zh) 2008-01-23
JP2008531480A (ja) 2008-08-14
TW200640940A (en) 2006-12-01
AU2006210008A1 (en) 2006-08-10
SI1848727T1 (sl) 2015-09-30
EP1848727B1 (en) 2015-06-17
IL184720A (en) 2014-12-31
EP1848727A1 (en) 2007-10-31
RU2007132700A (ru) 2009-03-10
CA2594717A1 (en) 2006-08-10
IL184720A0 (en) 2007-12-03
NO20073755L (no) 2007-08-28
KR100908530B1 (ko) 2009-07-20
KR20070100395A (ko) 2007-10-10
RU2387661C2 (ru) 2010-04-27
CN101111505B (zh) 2011-09-14
EP2363401A1 (en) 2011-09-07
JP2015205908A (ja) 2015-11-19
JP5828607B2 (ja) 2015-12-09
US7582789B2 (en) 2009-09-01

Similar Documents

Publication Publication Date Title
BRPI0607093A2 (pt) polimorfo cristalino de monoidrato de sal monossódico de ácido 3-(n-metil-n-pentil)amino-1-hidroxipropano-1, 1-difosfÈnico, ibandronato, processo para a preparação de um polimorfo de ibandronato cristalino, e composição farmacêutica que o compreende
BRPI0607092A2 (pt) polimorfo cristalino de monoidrato de sal monossódico de ácido 3-(n-metil-n-pentil) amino-1-hidroxipropano-1, 1-difosfÈnico, ibandronato, processo para a preparação de um polimorfo de ibandronato cristalino, e composição farmacêutica que o compreende
IL182690A0 (en) Process for the preparation of ibandronate
IL172513A0 (en) Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
TN2010000136A1 (en) Composition comprising sphingosine 1 phosphate (s1p) receptor modulators
BRPI0603059A (pt) forma cristalina v de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a
BRPI0603074A (pt) forma cristalina iii de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a
BRPI0514766A (pt) composições farmacêuticas
BRPI0905147A8 (pt) processo para síntese de ivabradina e seus sais de adição com um ácido farmaceuticamente aceitável
BRPI0519316B8 (pt) composição aquosa herbicida, e, processo para a preparação de uma composição
DOP2009000130A (es) Sal de potasio cristalina de analogos de lipoxina a4
BRPI0817747A8 (pt) Processo para a preparação de derivados de ácido 2-di-halogenoacil-3-amino-acrílico
BRPI0708278B8 (pt) forma cristalina "a" do sal de arginina de perindopril, seu uso, processo para sua preparação e composição farmacêutica
WO2007074475A3 (en) Novel polymorphic forms of ibandronate
MX359363B (es) Dihidroetorfina y su preparacion.
EA200600760A1 (ru) Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их
BRPI0606659A2 (pt) processos para a preparação de álcoois aminoetoxibenzìlicos
ZA200800138B (en) Process for the preparation of crystalline perindopril
CY1112979T1 (el) Διαδικασια για την παρασκευη της ενωσης (s)-1-αλκυλ-2',6'-πιπεκολοξυλιδιδιου
WO2007083243A3 (en) An improved process for the preparation of risedronate sodium hemi-pentahydrate
MX2009010850A (es) Sintesis de ibandronato en multiples etapas.
WO2008014510A3 (en) Crystalline form a of ibandronic acid and process for the preparation
BRPI0415857A (pt) método para preparar um composto, produto preparado por esse processo e composição que compreende o mesmo
CL2010000973A1 (es) Procedimiento de preparacion de la sal de clorhidrato de ester metilico del acido (e)-3-(4-{[2-(2-metil-1h-indol-3-il)etilamino]metil}fenil)-acrilico por combinacion de 2-metiltriptamina y el ester metilico del acido (e)-3-(4-formil-fenil)-acrilico, y posterior reduccion de la imina formada ( divisional de la sol. n° 1691-2007).
TH84983A (pt)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2498 DE 21-11-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI